Aqeel S, Faisal M, Akhtar O, Attwood K, George A, Advani P
Ann Hematol. 2024; 103(12):5539-5547.
PMID: 39495284
DOI: 10.1007/s00277-024-06075-2.
Kossow K, Bennett J, Cui W, Tun A, Kribs R
Cureus. 2024; 15(12):e50536.
PMID: 38222137
PMC: 10787663.
DOI: 10.7759/cureus.50536.
Vose J, Fu K, Wang L, Mansoor A, Stewart D, Cheng H
J Hematol Oncol. 2023; 16(1):122.
PMID: 38104096
PMC: 10725579.
DOI: 10.1186/s13045-023-01520-7.
Jain N, Mamgain M, Chowdhury S, Jindal U, Sharma I, Sehgal L
J Hematol Oncol. 2023; 16(1):99.
PMID: 37626420
PMC: 10463717.
DOI: 10.1186/s13045-023-01496-4.
Epperla N, Switchenko J, Bachanova V, Gerson J, Barta S, Gordon M
Blood Adv. 2022; 7(11):2287-2296.
PMID: 36516079
PMC: 10225877.
DOI: 10.1182/bloodadvances.2022009225.
Tackling Mantle Cell Lymphoma in Europe.
Horgan D, Walewski J, Aurer I, Visco C, Gine E, Fetica B
Healthcare (Basel). 2022; 10(9).
PMID: 36141294
PMC: 9498856.
DOI: 10.3390/healthcare10091682.
Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.
Elkjaer L, Cedile O, Hansen M, Nielsen C, Moller M, Abildgaard N
Leuk Res Rep. 2022; 18:100341.
PMID: 36039182
PMC: 9418493.
DOI: 10.1016/j.lrr.2022.100341.
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Freeman C, Pararajalingam P, Jin L, Balasubramanian S, Jiang A, Xu W
Leukemia. 2022; 36(10):2479-2487.
PMID: 35963941
DOI: 10.1038/s41375-022-01658-2.
First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: A Systematic Analysis and Treatment Recommendation.
Liu H, Shi X, Fang H, Cao L, Miao Y, Zhao X
Front Oncol. 2022; 12:881346.
PMID: 35646653
PMC: 9130771.
DOI: 10.3389/fonc.2022.881346.
Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma.
Lisson C, Lisson C, Mezger M, Wolf D, Schmidt S, Thaiss W
Cancers (Basel). 2022; 14(8).
PMID: 35454914
PMC: 9028737.
DOI: 10.3390/cancers14082008.
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Tbakhi B, Reagan P
Ther Adv Hematol. 2022; 13:20406207221080738.
PMID: 35237395
PMC: 8882938.
DOI: 10.1177/20406207221080738.
Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma.
Quinet G, Xolalpa W, Reyes-Garau D, Profitos-Peleja N, Azkargorta M, Ceccato L
Cancers (Basel). 2022; 14(4).
PMID: 35205670
PMC: 8869867.
DOI: 10.3390/cancers14040923.
Mantle cell lymphoma presenting with lethal atraumatic splenic rupture.
Eyerer F, Gardner J, Devitt K
Autops Case Rep. 2021; 11:e2021340.
PMID: 34805009
PMC: 8597805.
DOI: 10.4322/acr.2021.340.
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Castellino A, Wang Y, Larson M, Maurer M, Link B, Farooq U
Blood Adv. 2021; 6(4):1350-1360.
PMID: 34662895
PMC: 8864651.
DOI: 10.1182/bloodadvances.2021005715.
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
Bond D, Switchenko J, Villa D, Maddocks K, Churnetski M, Gerrie A
Blood Adv. 2021; 5(23):5179-5189.
PMID: 34516611
PMC: 9153047.
DOI: 10.1182/bloodadvances.2021004765.
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Riedell P, Hamadani M, Ahn K, Litovich C, Guru Murthy G, Locke F
Transplant Cell Ther. 2021; 27(11):911.e1-911.e7.
PMID: 34450333
PMC: 8556305.
DOI: 10.1016/j.jtct.2021.08.014.
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski M, Kolla B
Eur J Haematol. 2021; 107(3):301-310.
PMID: 33973276
PMC: 8338766.
DOI: 10.1111/ejh.13649.
Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis.
Zhou Y, Chen H, Tao Y, Zhong Q, Shi Y
J Cancer. 2021; 12(2):553-561.
PMID: 33391451
PMC: 7738989.
DOI: 10.7150/jca.51959.
Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995-2016: A SEER-Based Analysis.
Wu H, Wang J, Zhang X, Yang H, Wang Y, Sun P
Front Oncol. 2020; 10:588314.
PMID: 33194744
PMC: 7606943.
DOI: 10.3389/fonc.2020.588314.
Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?.
Epperla N, Vaughn J, Othus M, Hallack A, Costa L
Cancer Med. 2020; 9(15):5519-5525.
PMID: 32558356
PMC: 7402846.
DOI: 10.1002/cam4.3237.
